Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Maze Therapeutics, Inc.

Contributing Author

Recent Articles by Maze Therapeutics, Inc.

Sep-02
Maze Therapeutics to Participate in Three Upcoming Investor Conferences MAZE GlobeNewswire
Aug-13
Maze Therapeutics Announces Appointments to Its Board of Directors MAZE GlobeNewswire
Aug-11
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights MAZE GlobeNewswire
May-27
Maze Therapeutics to Participate in Two Upcoming Investor Conferences MAZE GlobeNewswire
May-12
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights MAZE GlobeNewswire
Apr-22
Maze Therapeutics Announces $150 Million Registered Offering MAZE GlobeNewswire
Mar-25
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights MAZE -35.24% GlobeNewswire
Mar-25
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease MAZE -35.24% GlobeNewswire
Feb-25
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference MAZE GlobeNewswire
Feb-04
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 MAZE GlobeNewswire
Jan-05
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference MAZE GlobeNewswire
Nov-06
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights MAZE GlobeNewswire
Nov-06
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week MAZE GlobeNewswire
Nov-04
Maze Therapeutics to Participate in Four Upcoming Investor Conferences MAZE GlobeNewswire
Oct-06
Maze Therapeutics Appoints Industry Veteran Herve Hoppenot as Chairman of the Board of Directors MAZE GlobeNewswire
Sep-11
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement MAZE +54.81% GlobeNewswire
Sep-11
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) MAZE +54.81% GlobeNewswire
Sep-02
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer MAZE +5.73% GlobeNewswire
Aug-12
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights MAZE GlobeNewswire
Jul-10
Maze Therapeutics to Participate in Two Upcoming Investor Conferences MAZE GlobeNewswire
May-29
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference MAZE +6.01% GlobeNewswire
May-14
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones MAZE -8.11% GlobeNewswire
May-13
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference MAZE GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)